Media
7NEWS Australia
New Sydney trial drug cures lymphoma patients with instant immunotherapy technology | 7NEWS Australia
Proactive Investors
Imugene raises A$2.42M in SPP to go towards azer-cel program
Proactive Investors
Inside Biotech: Can off-the-shelf CAR T finally deliver on its promise?
Proactive Investors
Imugene’s Leslie Chong talks Azer-cel breakthrough
Proactive Investors
Imugene posts 79% overall response rate in azer-cel Phase 1b trial
Proactive Investors
Imugene reports progress across clinical pipeline and bolsters capital position
Imugene Science Series
Chief Medical Officer John Byon and Principal Investigator, Azer-cel Phase 1b trial Dr Joseph Maakaron
Inside Precision Medicine
Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients
Targeted Oncology
Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses
Inside Precision Medicine
Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients
Pharma Biz
Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma
Applied Clinical Trials